{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:09:48Z","timestamp":1760954988632},"reference-count":11,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T00:00:00Z","timestamp":1181606400000},"content-version":"vor","delay-in-days":1684,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Congestive Heart Failure"],"published-print":{"date-parts":[[2002,11]]},"abstract":"<jats:p> <jats:italic>The International Enhanced External Counterpulsation (EECP) Patient Registry tracks acute and long\u2010term outcome for consecutive patients treated for chronic angina. Although EECP has previously been shown to be a safe and effective treatment for angina, little information is available on its use in patients with left ventricular (LV) dysfunction. This report compares the acute outcome and 6\u2010month follow\u2010up for a group of patients with severe LV dysfunction and a group of patients without LV dysfunction. Of 1402 patients in the registry recruited in 1998\u20131999 who had recorded values of LV ejection fraction (LVEF) at baseline, 1090 (77.7%) had preserved LV function (LVEF &gt;35%) and 312 (22.3%) had LV dysfunction (LVEF \u226435%). Six\u2010month follow\u2010up was available on 84% of these patients. Pre\u2010EECP patients with LV dysfunction had a longer history of coronary artery disease (12.9 years vs. 9.1 years;<\/jats:italic> p<jats:italic>&lt;0.001), a higher rate of congestive heart failure (60.6% vs. 20.1%<\/jats:italic> p<jats:italic>&lt;0.001) and myocardial infarction (83.5% vs. 61.9%<\/jats:italic> p<jats:italic>&lt;0.001). Patients with LV dysfunction had more severe pre\u2010EECP angina, with 86.2% presenting with Canadian Cardiovascular Society Class III\/IV vs. 73.6%<\/jats:italic> p&lt;<jats:italic>0.01. Patients with LV dysfunction, consistent with their more severe baseline profile, suffered more adverse events (death, unstable angina, and exacerbation of heart failure) during the treatment period and were less likely to complete the full course. Immediately post\u2010EECP, angina decreased by at least one class in 67.8% of patients with LV dysfunction (vs. 76.2%<\/jats:italic> p&lt;<jats:italic>0.01), and 35.9% of LV dysfunction patients vs. 39.0% had discontinued nitroglycerin use (<\/jats:italic>p=<jats:italic>NS). At 6\u2010month follow\u2010up, patients with LV dysfunction showed higher rates of death (9.3% vs. 2.2%<\/jats:italic> p&lt;<jats:italic>0.001) and exacerbation of congestive heart failure (9.9% vs. 3.7%<\/jats:italic> p&lt;<jats:italic>0.001). Rates of the composite outcome of death\/myocardial infarction\/coronary artery bypass grafting\/percutaneous coronary intervention (15.4% vs. 8.3%<\/jats:italic> p&lt;<jats:italic>0.001) were also higher for patients with LV dysfunction. However, patients not reporting such an event showed maintenance of their improved anginal status, with 81% of LV dysfunction vs. 83.8% of patients without LV dysfunction (<\/jats:italic>p=<jats:italic>NS) reporting angina at 6 months equal to or less severe than immediately post\u2010EECP, and nitroglycerin use was still reduced at 46.1% for LV dysfunction vs. 37.4% (<\/jats:italic>p&lt;<jats:italic>0.05). The rate of event\u2010free angina maintenance at 6 months was 67.0% for patients with LV dysfunction and 70.6% of patients with preserved LV function (<\/jats:italic>p=<jats:italic>NS). Patients with LV dysfunction achieved a less robust reduction in angina than did those without LV dysfunction. For the majority of the patients in the registry, this reduction was maintained at 6 months.<\/jats:italic><\/jats:p>","DOI":"10.1111\/j.1527-5299.2002.00286.x","type":"journal-article","created":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T11:20:18Z","timestamp":1181647218000},"page":"297-312","source":"Crossref","is-referenced-by-count":30,"title":["Enhanced External Counterpulsation as Treatment for Chronic Angina in Patients With Left Ventricular Dysfunction: A Report From the International EECP Patient Registry (IEPR)"],"prefix":"10.1111","volume":"8","author":[{"given":"Ozlem","family":"Soran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Kennard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl F.","family":"Kelsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Holubkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Strobeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur M.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,12]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00140-0"},{"key":"e_1_2_7_3_2","first-page":"339A","article-title":"Results of the Multicenter Enhanced External Counterpulsation (MUST\u2010EECP) Outcomes Study: quality of life benefits sustained twelve months after treatment [abstract]","volume":"33","author":"Arora RR","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00142-7"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240604"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240607"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)84078-8"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960220304"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.63.407"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2000.2545"},{"issue":"3","key":"e_1_2_7_11_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1071-9164(99)91617-2","article-title":"Enhanced external counterpulsation is a safe and effective treatment for angina pectoris in patients with severe left ventricular dysfunction","volume":"5","author":"Strobeck JE","year":"1999","journal-title":"J Card Fail"},{"issue":"1","key":"e_1_2_7_12_2","first-page":"5","article-title":"Efficacy and safety of enhanced external counterpulsation in mild to moderate heart failure: a preliminary report","author":"Soran O","year":"1995","journal-title":"J Card Fail"}],"container-title":["Congestive Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-5299.2002.00286.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-5299.2002.00286.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:37:58Z","timestamp":1697560678000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-5299.2002.00286.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["10.1111\/j.1527-5299.2002.00286.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-5299.2002.00286.x","archive":["Portico"],"relation":{},"ISSN":["1527-5299","1751-7133"],"issn-type":[{"value":"1527-5299","type":"print"},{"value":"1751-7133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}